Zoetis Net Cash Flow 2011-2025 | ZTS

Zoetis net cash flow for the twelve months ending March 31, 2025 was $-1.114B, a 78.97% decline year-over-year.

  • Zoetis annual net cash flow for 2024 was $-0.054B, a 96.49% decline from 2023.
  • Zoetis annual net cash flow for 2023 was $-1.54B, a 1704.17% decline from 2022.
  • Zoetis annual net cash flow for 2022 was $0.096B, a 180.67% decline from 2021.

Zoetis Net Cash Flow 2011-2025 | ZTS

  • Zoetis annual net cash flow for 2024 was $-0.054B, a 96.49% decline from 2023.
  • Zoetis annual net cash flow for 2023 was $-1.54B, a 1704.17% decline from 2022.
  • Zoetis annual net cash flow for 2022 was $0.096B, a 180.67% decline from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$67.5B
Daiichi Sankyo, - (DSNKY)$46.3B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$31.8B
Sandoz Group AG (SDZNY)$25.5B
Summit Therapeutics (SMMT)$21B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$13.6B
Neurocrine Biosciences (NBIX)$12.3B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.4B
Madrigal Pharmaceuticals (MDGL)$7.8B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$6.6B
Ionis Pharmaceuticals (IONS)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B
ARS Pharmaceuticals (SPRY)$1.6B